FTH Leads EPS Revision Rally with 68.9% Surge; CRMT, LILA Also Gain
Stocks flagged by our EPS revision screener surged in late June, led by Faeth Therapeutics (FTH) which jumped 68.9% from $14.53 to $24.54 after its forward EPS growth estimate was raised to 93.7%. Americas Car Mart (CRMT) gained 52.6% to $3.57 on a 101.7% growth estimate, while Liberty Latin America (LILA) rose 37.5% to $6.60 after a 131.8 percentage point revision. The moves occurred without specific earnings news, underscoring the power of estimate revisions in driving price.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FTH | Healthcare | 2026-06-16 | N/A | +68.9% |
| CRMT | Consumer Cyclical | 2026-06-16 | N/A | +52.6% |
| LILA | Communication Services | 2026-06-18 | +131.8pp | +37.5% |
| LILAK | Communication Services | 2026-06-18 | +1799.9pp | +36.7% |
| RYTM | Healthcare | 2026-06-15 | N/A | +19.9% |
Why did FTH stock jump in June 2026?
FTH jumped 68.9% (from $14.53 to $24.54) after its forward EPS growth estimate was raised to 93.7% on June 16.
The Healthcare sector saw broad momentum, and FTH's high growth estimate attracted investors seeking exposure to early-stage biotech. No earnings news emerged, but the screener captured the revision before the market priced it in, driving a strong revaluation.
FTH EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: FTH
Why did FTH stock jump in June 2026?
FTH jumped 68.9% after its forward EPS growth estimate was raised to 93.7% on June 16, from a detection price of $14.53 to a current $24.54.
Is FTH a buy after the rally?
With a 93.7% forward EPS growth estimate, FTH still offers high growth potential, but the 68.9% surge may have priced in much of the revision; consider valuation relative to peers.
What is FTH's EPS growth estimate?
FTH's current EPS growth estimate for next year is 93.7%, as of the June 16 revision detection.
Why did CRMT stock jump in June 2026?
CRMT jumped 52.6% (from $2.34 to $3.57) after its forward EPS growth estimate was raised to 101.7% on June 16.
The Consumer Cyclical sector benefited from improving economic signals, and CRMT's high growth estimate made it a standout among small-cap value plays. No specific news accompanied the move, reinforcing the revision as the primary catalyst.
CRMT EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: CRMT
Why did CRMT stock jump in June 2026?
CRMT rose 52.6% from $2.34 to $3.57 after its forward EPS growth estimate was raised to 101.7% on June 16.
What caused CRMT's surge?
The surge was driven by an upward EPS estimate revision to 101.7% growth, detected by our screener on June 16, with no additional earnings news.
What is CRMT's EPS growth estimate?
CRMT's current forward EPS growth estimate is 101.7% for next year.
Why did LILA stock jump in June 2026?
LILA jumped 37.5% (from $4.80 to $6.60) after analysts raised its forward EPS growth estimate from 208.4% to 340.3% on June 18.
The Communication Services sector rallied on renewed interest in emerging market telecoms, and LILA's dramatic estimate revision signaled improving fundamentals despite no specific news. The 131.8 percentage point revision highlighted a sharp expected turnaround.
LILA EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILA
Why did LILA stock jump in June 2026?
LILA jumped 37.5% from $4.80 to $6.60 after its forward EPS growth estimate was revised upward by 131.8 percentage points to 340.3% on June 18.
Is LILA a buy after the rally?
The 340.3% growth estimate is extremely high, but may reflect a low base; investigate underlying business trends before buying after the 37.5% gain.
What is LILA's EPS growth estimate revision?
LILA's forward EPS growth estimate was raised from 208.4% to 340.3% (a +131.8 pp revision) on June 18.
Why did LILAK stock jump in June 2026?
LILAK jumped 36.7% (from $4.79 to $6.55) after analysts raised its forward EPS growth estimate from 413.6% to 2,213.6% on June 18.
This extreme revision, likely due to a low base, attracted momentum traders. Both LILA and LILAK track Liberty Latin America; the sharper upward revision for LILAK signals an even more dramatic expected earnings rebound.
LILAK EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILAK
Why did LILAK stock jump in June 2026?
LILAK jumped 36.7% from $4.79 to $6.55 after its forward EPS growth estimate was raised from 413.6% to 2,213.6% on June 18.
What caused LILAK's surge?
The surge was driven by a massive 1,799.9 percentage point upward revision to its EPS growth estimate, detected by our screener on June 18.
What is LILAK's EPS growth estimate revision?
LILAK's forward EPS growth estimate soared from 413.6% to 2,213.6% (a +1799.9 pp revision) on June 18.
Why did RYTM stock jump in June 2026?
RYTM jumped 19.9% (from $89.70 to $107.55) after its forward EPS growth estimate was raised to 76.7% on June 15.
The Healthcare sector saw strength in specialty pharma, and RYTM's consistent growth outlook supported the rally. No earnings news accompanied the move, highlighting the screener's ability to capture estimate-driven price action.
RYTM EPS revision history → · Screener snapshot from 2026-06-15 →
FAQ: RYTM
Why did RYTM stock jump in June 2026?
RYTM rose 19.9% from $89.70 to $107.55 after its forward EPS growth estimate was raised to 76.7% on June 15.
Is RYTM a buy after the rally?
With a 76.7% growth estimate and a 19.9% gain, RYTM still offers upside if the estimate proves conservative, but consider the stock's high absolute price.
What is RYTM's EPS growth estimate?
RYTM's current forward EPS growth estimate is 76.7% for next year, as of the June 15 revision detection.
The broad-based gains across healthcare, consumer cyclical, and communication services sectors suggest that investors are rewarding companies with strong forward earnings growth potential, even in the absence of news catalysts. The EPS revision screener continues to identify mispriced opportunities ahead of the market.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →